Sperimentazioni cliniche

Vemurafenib plus Rituximab as a chemotherapy-free alternative to Cladribine followed by MRD-guided Rituximab in front-line hairy Cell leukemia (HCL): a phase-2 randomized multicenter trial

An Observational Retrospective Cohort Study of Lenalidomide Monotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) to Generate a Historical Control for Clinical Trial MOR208C206.

Nursing Intervention to Strengthen Medication Adherence after allogeneic Transplantation (NISMAT).

Efficacia e Sicurezza del Luspatercept per il Trattamento dell’Anemia dovuta alle Sindromi Mielodisplastiche con del5q refrattarie/resistenti/intolleranti a precedenti Trattamenti e che richiedono Trasfusioni di Globuli Rossi (QOL-ONE Phoenix).

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q, refractory/resistant/intolerant to Prior Treatments, Who Require Red Blood Cell Transfusions (QOL-ONE Phoenix).

Upadacitinib treatment patterns, achievement of treatment targets and maintenance of response in moderate to severe Rheumatoid Arthritis patients in real-world practice. (UPHOLD)

Estensione in aperto di fase 3, a braccio singolo, multicentrica, dello studio ARGX-113-2007 per valutare la sicurezza, la tollerabilità e l’efficacia a lungo termine di efgartigimod PH20 SC in partecipanti di età pari o superiore a 18 anni con miopatia infiammatoria idiopatica attiva.

A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy.

Studio di fase 3 randomizzato, in doppio cieco, controllato con placebo per valutare l’efficacia e la sicurezza di Dazodalibep nei partecipanti con sindrome di Sjögren con attività di malattia sistemica da moderata a grave.

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity.

Studio multicentrico, di estensione in aperto per valutare l’efficacia, la sicurezza e la tollerabilità di HZN-825 in pazienti con sclerosi sistemica cutanea diffusa.

A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis.

Studio di Fase 3, randomizzato, in doppio cieco, controllato con placebo volto a valutare l’efficacia e la sicurezza di Dazodalibep in partecipanti con sindrome di Sjögren con stato sintomatologico da moderato a grave

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State.

A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthrits-